The Unsurprising Reason Cara Therapeutics Fell Over 16% Today
Image source: Getty Images.
What happened
Shares of Cara Therapeutics (NASDAQ: CARA), a pre-revenue biopharma company focused on developing treatments for inflammation and pain, fell over 16% today. This appears to be a sign that investors are allowing the stock to cool off after a 70% rise from the beginning of the month to Nov. 16.
So what
Today's move comes days after an analyst upgraded the stock, which promptly sent shares over 25% higher. It's been a wild year for Cara Therapeutics, which fell dramatically to start the year, but has recovered substantial ground since September. The stock is down 37.8% year to date, but has risen 68% in the last six months:
Excitement is building for Cara Therapeutics, as it expects to announce results for its three leading clinical programs in the next six months. The trials announcing data are investigating the safety and efficacy of its lead drug candidate, CR845. The studies include a phase 3 trial for postoperative pain (intravenously administered CR845), a phase 2 trial for chronic pain (oral CR845), and a phase 3 trial for the severe skin-itch condition known as pruritus (intravenous CR845). The company's only other drug candidate, CR701, has yet to begin phase 1 trials.
Of course, given the pre-revenue nature of the company, investors should be reminded that the next six months could also determine its fate. If all of the trials fail, then investors will be left with one early-stage drug and a greatly reduced cash pile. If two or three of the trials succeed, then investors could be in for considerable upside. It remains a risky, binary bet.
Now what
Investors can expect continued volatility for Cara Therapeutics heading into the announcement of trial results, as the market nervously considers all possible outcomes. After data are released, all bets are off.
10 stocks we like better than Cara Therapeutics When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Cara Therapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of November 7, 2016
Maxx Chatsko has no position in any stocks mentioned. Follow him on Twitterto keep up with developments in engineered biology and materials science.
The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.